somatostatin Report issue

Biologics Recombinant protein Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Somatostatin, also known as growth hormone-inhibiting hormone (GHIH) or by several other names, is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Somatostatin inhibits insulin and glucagon secretion.   Wikipedia

Chemistry

  • SMILES: C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O
  • InChIKey: NHXLMOGPVYXJNR-ATOGVRKGSA-N
  • Mol. Mass: 1637.91
  • ALogP: Missing data
  • ChEMBL Molecule:
    somatostatin  
More Chemistry

Pharmacology

Alternative names

aminopan | growth hormone release-inhibiting factor | somatostatin | somatotropin release-inhibiting hormone | srif-14

Organizations (76)

Research & Development (76)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (1)


 

Hemorrhage

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Carcinoid Tumor (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Islet Cell (Phase 2)

Diabetic Retinopathy (Phase 2/Phase 3)

End Stage Liver Disease (Phase 4)

Esophageal and Gastric Varices (Phase 4)

Gallbladder Neoplasms (Phase 3)

General Surgery (Phase 3)

Growth and Development (Phase 2)

Healthy Volunteers (Phase 4)

Hemorrhage (Phase 4)

Hypertension, Portal (Phase 4)

Hypoglycemia (Phase 1)

Infant, Small for Gestational Age (Phase 2)

Intestinal Diseases (Phase 4)

Intestinal Neoplasms (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Failure (Phase 3)

Neuroendocrine Tumors (Phase 2)

Pancreatic Diseases (Phase 2/Phase 3)

Pancreatic Fistula (Phase 4)

Pancreatic Neoplasms (Phase 4)

Pancreatitis (Phase 3)

Pancreatitis, Acute Necrotizing (Phase 4)

Peptic Ulcer (Phase 2)

Polycystic Kidney, Autosomal Dominant (Phase 3)

Prostatic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 4)

Turner Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial Organizations: 76

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue